Trial Profile
Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS): A Randomized, Two-Arm, Parallel, Double-Blind, Multi-Centre, Placebo Controlled Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Postpoliomyelitis syndrome
- Focus Therapeutic Use
- Sponsors Calliditas Therapeutics; Pharmalink AB
- 25 Jun 2014 New trial record